Showing 1851-1860 of 5660 results for "".
DermWireTV: Climate Change and Skin, Wynzora, Tremfya, Rinvoq Updates
https://practicaldermatology.com/topics/psoriasis/dermwiretv-climate-change-and-skin-wynzora-tremfya-rinvoq-updates/19834/The vast majority of dermatologists around the world—95.6 percent—believe climate change is occurring, and 88 percent think it will impact the incidence of skin diseases, according to the first international survey of dermatologists on the topic, conducted online by the International Society of DermSkin Cancer Prevention–Present and Future
https://practicaldermatology.com/programs/practical-dermatology/skin-cancer-prevention-present-and-future/18193/A panel discussion led by Neal Bhatia, MD, reveals the efforts – large and small – being made by dermatologists Laura Ferris, MD, Vishal Patel, MD, and Todd Schlesinger, MD, to combat skin cancer in their clinics and in their communities.Photoprotection in Diverse Patient Populations
https://practicaldermatology.com/programs/practical-dermatology/photoprotection-in-diverse-patient-populations/18196/In part one of a three-part podcast series on dermatologic issues facing patients with darker skin tones, Drs. Andrew Alexis, Corey Hartman, and Janiene Luke discuss photoprotection and why it matters for all patients.Psoriasis Challenges and Alopecia Areata Advances
https://reachmd.com/programs/practical-dermatology/psoriasis-challenges-and-alopecia-areata-advances/39885/Mona Shahriari, MD, FAAD, talks about the challenges psoriasis poses in certain parts of the body such as the scalp and nails, plus Brittany Craiglow, MD, FAAD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss the latest advances in alopecia areata.New Analysis of Benzene Contamination in BPO Products
https://practicaldermatology.com/series/dermwire-tv/new-analysis-benzene-contamination-bpo-products/29074/In this week's DermwireTV, new data continues to raise concerns about benzene contamination in BPO products; the FDA expands the approved dosage for Ameluz for actinic keratosis (AK); and in our PA Perspectives segment, Andrew Mastro discusses how to approach a contract negotiation.Addressing the Psychologic Impact of Atopic Dermatitis on Pediatric Patients
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/addressing-the-psychologic-impact-of-atopic-dermatitis-on-pediatric-patients/37174/Elizabeth Lippner, MD, MA, Attending Physician in the Division of Allergy and Immunology and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, describes the psychologic impact of atopic dermatitis on children and how clinicians can address these issues.New FDA Approval for AD
https://practicaldermatology.com/series/c-suite-chats/new-fda-approval-for-ad/29911/Phil Brown, MD, JD, Dermatologic Scientific Lead at Organon, talks about the importance of a new FDA-approved topical solution for treating atopic dermatitis.DermWireTV: Atopic Dermatitis Pipeline Watch, a Potential New Skin Cancer Treatment; Demystifying Itch, and the Premiere of PA Perspectives
https://practicaldermatology.com/topics/practice-management/dermwiretv-atopic-dermatitis-pipeline-watch-a-potential-new-skin-cancer-treatment-demystifying-itch-and-the-premiere-of-pa-perspectives/20228/Escient Pharmaceuticals, Rapt Therapeutics, and Connect Biopharma each report positive results from early clinical studies in AD. Finnish researchers discover a potential treatment for cutaneous squamous cell carcinoma in an existing chemotherapy drug. Research out of Harvard Medical School links ecWeighing the Role of Network Meta-analysis for Choosing Biologic Therapies in Psoriatic Disease
https://practicaldermatology.com/programs/practical-dermatology/weighing-the-role-of-network-meta-analysis-for-choosing-biologic-therapies-in-psoriatic-disease/18189/There’s no paucity of studies for biologic therapies used to treat psoriatic disease, but the number of head-to-head trials comparing these agents is limited. Enter network meta-analysis, a statistical methodology that has emerged over the past few years to compare medication. Philip Mease, MD, a clDWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/programs/practical-dermatology/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.